Varicella-zoster virus (VZV) causes chickenpox and shingles. VZV is released from infected cells during natural infection, but remains highly cell-associated during experimental infection, and so most studies have utilized cell-associated infection models. We examined the impact of cell-free VZV infection of primary human foreskin fibroblasts (HFFs) on the receptor integrin a6 (ITGA6). qPCR and flow cytometry demonstrated that both cell-free VZV and cell-free UV-inactivated VZV downregulated transcription and cell-surface protein expression of ITGA6. To establish whether ITGA6 altered VZV infection, VZV transcripts and nuclear DNA levels were measured in HFFs treated with ITGA6 blocking antibody before infection. ITGA6 blocking did not impair virus entry but did negatively impact VZV transcription, and this effect was virus specific as transcription of the related herpes simplex virus type 1 was not similarly inhibited. This study identifies modulation of ITGA6 during cell-free VZV infection, and provides the first evidence linking ITGA6 with postentry productive VZV gene expression.
Varicella-zoster virus (VZV) is a human herpesvirus that is the causative agent of two clinically distinct diseases. Upon primary exposure to the virus, it causes the common childhood disease of varicella (chickenpox). The virus then has the ability to establish a life-long latency in sensory ganglia of infected individuals, and can reactivate later on in life to cause herpes zoster (shingles) (Arvin, 2001; Cohen et al., 2007) . During productive infection VZV gene transcription is believed to follow a temporally regulated cascade, with immediate-early (IE) genes, expressed in the absence of de novo protein synthesis, followed by early (E) genes and finally late (L) genes (Honess & Roizman, 1974) . VZV is highly species specific, limiting the capacity to use animal models for the study of productive VZV replication (Cohen et al., 2007) . The virus is also very highly cellassociated in cell culture, and as such it is difficult to obtain high titres of cell-free virus (Carpenter et al., 2009; Grose et al., 1979; Weller, 1953) . For this reason, most studies examining VZV-host cell interactions have utilized a cellassociated means of infection, whereby uninfected cells are experimentally infected by mixing with productively infected cells. These include analyses of the global impact of VZV on host cell gene expression (Jones & Arvin, 2003 , but there has been a paucity of work examining infection with cell-free VZV, despite cell-free VZV being a common feature of natural infection of humans (Ozaki et al., 1996) .
Integrins are cell-surface molecules that have been shown to play a role in cell-to-cell adhesion (Mercurio, 1995) and cell migration mechanisms (Wang et al., 2005) . They have been identified on many different cell types, particularly in cells of an epithelial nature (Müller et al., 2008) . They interact strongly with the extracellular matrix, adhering to fibronectin and laminin in the basement membrane (Kajiji et al., 1987 (Kajiji et al., , 1989 . Integrin molecules contain both an aand b-subunit. Eleven variants of the a-chain exist (Ruoslahti & Giancotti, 1989) as well as six variants of the b-chain (Sheppard et al., 1990) .
Integrins have been identified as receptors for viral entry into host cells, or as being modulated by viral gene expression, including by herpesviruses such as herpes simplex virus type 1 (HSV-1) (Gianni et al., 2010; Parry et al., 2005) , human cytomegalovirus (HCMV) (Feire et al., 2004; Wang et al., 2005) , Epstein-Barr virus (EBV) (Chesnokova et al., 2009; Hutt-Fletcher & Chesnokova, 2010; Pegtel et al., 2005) and Kaposi's sarcoma-associated herpesvirus (KSHV) (Kerur et al., 2010; Veettil et al., 2008) . VZV upregulates integrin a3 (ITGA3) mRNA in human T-cells and fibroblasts infected with cell-associated virus, although the functional consequence of this upregulation has not been reported (Jones & Arvin, 2003) . Integrin a6 (ITGA6) has been shown to act as a receptor for HCMV entry into fibroblasts, though it is not required for viral attachment to these cells (Feire et al., 2004) . Human papillomavirus (HPV), a non-herpesvirus, has also been identified as utilizing ITGA6 as a receptor for infection (Evander et al., 1997) . In the current study, we examined the impact of cell-free VZV infection of primary human foreskin fibroblasts (HFFs), focussing on ITGA6, as a preliminary microarray-based screen of cellular transcription following cell-free VZV infection of HFFs indicated that ITGA6 transcription was downregulated twofold in comparison to mock-infected HFFs (J. B. Bowles, B. Slobedman and A. Abendroth, unpublished data).
We sought to determine whether VZV modulated the expression of ITGA6 in primary HFFs following infection with cell-free VZV strain S (Moffat et al., 1995 (Moffat et al., , 1998 or cell-free VZV inactivated by UV-irradiation (UVStratalinker; 10 cycles at 9.9610 5 mJ per cycle). Analysis of cells inoculated with UV-inactivated cell-free VZV (UV-VZV) was included to investigate whether any changes observed occurred as a result of viral attachment and entry into the host cell in the absence of de novo viral gene expression. To prepare stocks of cell-free VZV, infected HFFs were washed in cold PBS, then incubated with 0.1 % EDTA 3Na/PBS for 5 min before the cells were harvested, washed and resuspended in PBS/sucrose/glutamate/FCS solution (PSGC). Cells were sonicated (Branson digital 450 sonifier) and the clarified supernatant collected. Cell-free virus was frozen prior to use, and the virus titre was determined prior to infection of fibroblast monolayers. Prior to infection, the PSGC inocula were diluted in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % FCS. Mock-infected cell-free preparations were obtained in exactly the same manner using uninfected HFFs. HFFs were either mock infected, or infected with cell-free VZV at an m.o.i. of 1, or an equivalent amount of UV-inactivated cell-free VZV. An m.o.i. of 1 provided a good balance between available titres of cell-free VZV and the number of cells to be infected. This m.o.i. resulted in 50-70 % of each HFF monolayer being infected (data not shown).
At 6 and 24 h post-infection (p.i.), total RNA was extracted (RNAqueous kit; Ambion) and 1 mg RNA was treated with DNase I (Promega) before being reverse transcribed using random hexamers. Real-time RT-PCR (qRT-PCR) was performed using primers to detect ITGA6 (forward 59-TCAATTGCTGGAAACATGGA-39, reverse 59-GGCGGA-GGTCAATTCTGTTA-39). Fold changes in ITGA6 transcripts were determined following normalization to the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Bustin, 2000) (forward 59-TCACCA-GGGCTGCTTTTAAC-39, reverse 59-GACAAGCTTCCCG-TTCTCAG-39). Analysis of at least four independent biological replicate experiments revealed that ITGA6 transcripts were significantly downregulated (P,0.05) by both cell-free VZV and cell-free UV-inactivated VZV at 6 h p.i., and that this downregulation was maintained at 24 h p.i. (Fig. 1 ).
To determine whether the observed decrease in ITGA6 transcription resulted in a subsequent decrease in cellsurface protein expression, HFFs were inoculated with either mock inoculum, cell-free VZV at an m.o.i. of 1, or an equivalent amount of cell-free UV-VZV. At 24 h p.i., cells were immunostained with either an ITGA6 antibody (clone 4F10; QED), or with an antibody to the transferrin receptor CD71 (clone MA-712; BD Pharmingen), which has been shown to be unaltered by VZV infection (Abendroth et al., 2000) . In parallel, cells were also incubated with the appropriate isotype control antibodies. The level of cell surface expression of ITGA6 and CD71 was determined by flow cytometry (Fig. 2) . In comparison with mock-infected cells, levels of cell surface CD71 remained unaltered following infection with either cell-free VZV, or cell-free UV-VZV. In contrast, both cell-free VZV and cell-free UV-VZV decreased cell surface expression of ITGA6, and analysis of four replicate independent experiments demonstrated this decrease to be statistically significant (P,0.005). Thus, cellfree VZV and cell-free UV-VZV downregulated ITGA6 transcription was reflected by reduced cell-surface ITGA6 protein expression. The capacity of cell-free UV inactivated VZV to downregulate ITGA6 in a manner comparable to viable cell-free VZV is consistent with a virion factor functioning to negatively impact ITGA6 expression, or a cellular response to VZV binding/entry. Future studies will therefore include a focus on identifying any virion factor(s) which may function to inhibit ITGA6 expression.
Previous studies have reported that ITGA6 can act as a receptor for HCMV entry into fibroblasts, though it is not required for viral attachment to these cells (Feire et al., 2004) . Non-herpesviruses have also been identified as utilizing ITGA6 as a receptor, including HPV (Evander et al., 1997) . We therefore sought to determine whether modulation of ITGA6 may alter VZV infection of HFFs, by examining VZV transcription and VZV nuclear DNA levels in cells in which cell surface ITGA6 protein had been blocked prior to infection. HFFs were incubated for 1 h with either clone GoH3 (BD Pharmingen), the ITGA6 blocking antibody (Evander et al., 1997; Feire et al., 2004) at a dilution of 1 : 100 in DMEM supplemented with 10 % FCS, a previously established effective concentration for ITGA6 blockade (Evander et al., 1997) , or a corresponding amount of rat IgG isotype control.
Cells were then infected with cell-free VZV at an m.o.i. of 1. At 6 and 24 h p.i., RNA was extracted, treated with DNase I and analysed by qRT-PCR to determine the relative expression level of a range of VZV transcripts spanning all three kinetic classes of viral genes, specifically the IE gene products of IE61 (forward 59-ATTCCATC-GACATCCTACCG-39, reverse 59-CTCTAGCCGACGAT-TGAAGG-39), IE62 (forward 59-TAATGGGCTCGCCTG-TAATC-39, reverse 59-GTTCATCGGTGGTTTTGGAG-39), IE63 (forward 59-GAGGAGAGCACCGATTCTTG-39, reverse 59-CTTTCGCGGCTGTATATTCC-39), IE4 (forward 59-GAACCTTCGGATGACTTTGC-39, reverse 59-TCGTT-TGGAATACCGTGGAT-39), the early (E) gene products of ORF16 (forward 59-GGTGATTGTGGTCCAGATGA-39, reverse 59-GTCGCTGTAAACGGGTGAAT-39), ORF18 (forward 59-GTTCGCGGCTATTGCATATT-39, reverse 59-CTGGT-GATAGCGGGTTTTTC-39), ORF29 (forward 59-GCCCAA-ATTCTGCGTTGTAT-39, reverse 59 GTGGCCATCTCG-ATCTGTTT-39), ORF28 (forward 59-TCGTGGGGATAA-GTTTGACC-39, reverse 59-CGGGACATGCCAAGTAA-AGT-39), and the late (L) gene products of gB (forward 59-CCAGACCTACCTTGCCAGAG-39, reverse 59-TCGTC-GGGATCTGGTATTTC-39), gC (forward 59-CACGTGG-CGTTGTACATTTC-39, reverse 59-TGATAGGTCCGTCG-AGTTCC-39), gE (forward 59-CCGAGACTTGGAGCTT-TTTG-39, reverse 59-CGGCCAACTGATCCTCTTTA-39). These data were normalized to the level of expression of GAPDH transcripts and the results expressed as the fold difference in VZV transcript levels in cells pre-treated with the GoH3 ITGA6 blocking antibody in comparison to the same transcript levels in cells pre-treated with the isotype control antibody. At 6 h p.i., all of the VZV genes examined showed a statistically significant decrease in transcript levels as a result of pre-treatment with the ITGA6 blocking antibody, following at least three biological replicate experiments Statistical significance from four independent biological replicate experiments (n54) was determined by Student's t-test (*P,0.05, **P,0.005).
Inhibition of ITGA6 by VZV (Fig. 3a) . For the majority of these genes this statistically significant decrease was maintained at 24 h p.i., although for some of these genes (IE62, IE61, ORF16 and VZV gB) the decrease was not statistically significant at this later time point (Fig. 3b) . This data indicates that pre-treatment of HFFs with an ITGA6 blocking antibody prior to infection results in decreased VZV transcription.
To determine whether the decrease in VZV gene transcription following pre-treatment of HFFs with ITGA6 blocking antibody was a consequence of a block in VZV entry into these cells, we utilized qPCR to examine the levels of VZV DNA in the nuclei of infected cells with pretreatment with the ITAG6 blocking antibody or isotype control antibody. At 6 and 24 h p.i., nuclei were extracted from cells using the Nucbuster Extraction kit (Novagen). Nuclei were lysed and treated to preserve DNA using a lysis buffer (Kondo et al., 1994; Slobedman & Mocarski, 1999) before qPCR to detect VZV DNA using primers specific for VZV ORF16. In three independent biological replicates, the relative level of VZV DNA remained comparable in HFFs pre-treated with the ITAG6 blocking antibody or the isotype control antibody. This was true at both time points tested (Fig. 3c ). Taken together with the analyses of VZV transcription levels, these data indicate that pre-treatment of HFFs with ITGA6 blocking antibody did not impair virus entry into these cells, but did negatively impact subsequent VZV gene transcription. It remains to be determined whether ITGA6 also influences VZV genome replication and virus spread, and this will be the focus of additional studies to fully define the impact of ITGA6 on VZV infection.
To determine whether HFFs pre-treated with ITGA6 blocking antibody retained the capacity to support viral gene expression of a closely related virus, these experiments 6 h p.i. were repeated using another alpha-herpesvirus, HSV-1, which exhibits the highest homology with VZV (Davison & Scott, 1986) . To date, ITGA6 has not been identified as playing a role in HSV-1 entry. Four HSV-1 genes were selected for analysis of transcription by qRT-PCR. These spanned the three kinetic classes of HSV-1 replication and each HSV-1 gene also shares homology with one of the VZV genes analysed. The HSV-1 genes selected were UL27 (homologous to VZV gB), UL29 (homologous to VZV ORF29), UL30 (homologous to VZV ORF28) and UL54 (homologous to VZV IE4) (Cohen & Straus, 2001; Cohen et al., 2007; Davison & Scott, 1986) .
To examine any changes in transcription of HSV-1 following cell-free virus HSV-1 infection of HFFs, we used the same m.o.i. of 1 as used for VZV infection. HFFs pretreated with the ITGA6 blocking antibody were examined in comparison to cells pre-treated with isotype control antibody. The results from three independent replicate experiments revealed that there was no significant difference in HSV-1 transcription levels of any of the four genes between treatment with isotype control and ITGA6 blocking antibody at either 6 or 24 h p.i. (Fig. 3d, e) . These data indicate that the post-entry inhibition VZV transcription in cells pre-treated with ITGA6 blocking antibody was VZVspecific as this effect was not observed in the context of HSV-1 infection of the same cells.
This study identifies modulation of ITGA6 as a feature of cell-free VZV infection, and provides the first evidence connecting ITGA6 with post-entry productive VZV gene expression. The precise mechanism by which disruption of ITGA6 leads to reduced VZV transcription following cellfree virus infection is yet to be determined, but this may be linked to signalling pathways such as the Ras-MAP kinase (Payne et al., 2001 ) and the PI3 kinase pathways (Fothergill & McMillan, 2006) , which are stimulated by engagement of this receptor. Integrin signalling has been shown to negatively regulate virus replication. For example, HIV-1 replication can be reduced by the blockade of integrin aV (Ballana et al., 2009) , and blockade of integrin b5 contributes to this effect (Ballana et al., 2011) . Whether downregulation of ITGA6 is a direct result of a VZVencoded protein, or whether VZV indirectly downregulates ITGA6 via modulation of an as-yet-unidentified cellular factor(s) will require studies using purified cell-free VZV virions. Similarly, the question remains as to whether VZV actively represses ITGA6 following virus binding/entry or whether the downregulation of ITGA6 is a host cellular response that is aimed at reducing the efficiency of VZV replication.
